| Company | Amount/Round | Lead Investors | Description |
|---|---|---|---|
| Portola Pharmaceuticals South San Francisco | $60M FThird | D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK | Most of the funding will be used to advance Portola's lead drug betrixaban. |
| Light Sciences Oncology Bellevue, WA | $40.1 Third | Unnamed | The funding will be used to advance its work on light infusion therapies. |
| Dicerna Pharmaceuticals Cambridge, MA | $8.4M First | Abingworth, Oxford Bioscience Partners and Skyline Ventures | Dicerna Pharmaceuticals is an RNA interference company. |
Portola leads with $60M round